Table 2.
Number of E. coli samples with antimicrobial susceptibility testing (AST) by origin across 18 departments in the years 2008–2016
| Origin of the samples | Tested for | All nosocomial samples (N = 2330) | Samples obtained after 2 to 5 hospital days (N = 525) | Samples obtained after 5 hospital days (N = 1805) |
|---|---|---|---|---|
| Urine | AM-CL, Amox/AMP, Quinolones, TMP-SMX | 1503 (65%) | 377 (72%) | 1126 (62%) |
| CFP | 256 (11%) | 53 (10%) | 203 (11%) | |
| CFT, Gent, MERa, PIP-TZ, | 258 (11%) | 55 (10%) | 203 (11%) | |
| Blood | AM-CL, Amox/AMP, CFP, CFT, Gentamicin, MERa, PIP-TZ, Quinolones, TMP-SMX | 264 (11%) | 32 (6%) | 232 (13%) |
| Respiratory -tract | AM-CL, Amox/AMP, CFP, CFT, Gent, MERa, PIP-TZ, Quinolones, TMP-SMX | 86 (4%) | 29 (6%) | 57 (3%) |
| Wound swabs | AM-CL, Amox/AMP, CFP, CFT, Gent, MERa, PIP-TZ, Quinolones | 83 (4%) | 12 (2%) | 71 (4%) |
| TMP-SMX | 82 (4%) | 12 (2%) | 70 (4%) | |
| Other | AM-CL, Amox/AMP, CFP, CFT, Gent, MERa, PIP-TZ, Quinolones, TMP-SMX | 394 (17%) | 75 (14%) | 319 (18%) |
Abbreviations: Amox amoxicillin, AMP ampicillin, AM-CL amoxicillin-clavulanic acid, CFP cefepime, CFT ceftriaxone, Gent gentamicin, MER meropenem, PIP-TZ piperacillin-tazobactam, TMP-SMX trimethoprim-sulfamethoxazole
aNot included in the models for resistance because all samples were susceptible to Meropenem